At a glance
ClinicalIndex Comparison RecordN/ACompleted· 26 enrolled
Drug / intervention
BCAA Supplement +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BCAA Supplemental Study: Branched Chain Amino Acid and Physical Activity to Improve Muscle Mass in Patients With Cirrhosis
In Brief
A clinical study evaluating BCAA Supplement and Physical Activity for Cirrhosis. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The central hypothesis of this study is that BCAA supplementation and BCAA supplementation plus low-intensity activity will improve muscle mass and HRQOL in cirrhotic patients compared to usual care
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCirrhosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedNov 2017
Primary CompletionJun 2019
TodayJul 2026
First PostedNov 13, 2017
Enrollment StartOct 2, 2017
Primary CompletionJun 17, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.6 years ago
Interventions
BCAA Supplementdietary
Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio.
Physical Activityother
Supervised low impact aerobic physical activity for one hour each week.